COVID-19 patients presented similar levels of anti-RBCL, anti-PS, and anti-DNA as patients with malaria, another highly inflammatory infectious disease, but lower levels than patients with SLE. The gene discussed is PRB2; the disease is systemic lupus erythematosus.